Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity - a rebuttal

被引：15
|
作者：
Sallah, S
Isaksen, M
Seremetis, S
Rojkjaer, LP
机构：
[1] Novo Nordisk AS, Biopharm, DK-2880 Bagsvaerd, Denmark
[2] Novo Nordisk AS, Int Prod Safety, DK-2820 Gentofte, Denmark
[3] Novo Nordisk AS, Med Dev, DK-2880 Bagsvaerd, Denmark
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2005年 / 3卷 / 04期
关键词：
D O I：
10.1111/j.1538-7836.2005.01254.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：820 / 822
页数：3
相关论文
共 50 条
  • [21] EXTRINSIC COAGULATION PATHWAY INHIBITOR DURING RECOMBINANT FACTOR-VIIA INFUSION
    SANDSET, M
    ABILDGAARD, U
    HEDNER, U
    JOHANSSON, H
    [J]. THROMBOSIS AND HAEMOSTASIS, 1989, 62 (04) : 1146 - 1146
  • [22] Use of recombinant factor VIIA plus continuous infusion of recombinant factor VIII in the hemostasis of type 3 von Willebrand disease with anaphylactic anti-VWF inhibitor
    Suzuki, N.
    Sanda, N.
    Matsushita, T.
    Kojima, T.
    Yamamoto, K.
    Katsumi, A.
    Hirashima, K.
    Kajiura, Y.
    Takatsu, M.
    Naoe, T.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 665 - 665
  • [23] Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa
    Sheth, S
    DiMichele, D
    Lee, M
    Lamour, J
    Quaegebeur, J
    Hsu, D
    Addonizio, L
    Piomelli, S
    [J]. HAEMOPHILIA, 2001, 7 (02) : 227 - 232
  • [24] Successful use of recombinant factor VIIa for emergency fasciotomy in and high-titer inhibitor a patient with hemophilia a unresponsive to factor VIII inhibitor bypassing activity
    Watts, RG
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2005, 79 (01) : 58 - 60
  • [25] Pseudoprolongation of the Prothrombin Time During Treatment with Recombinant Factor VIIa for Bleeding in a Patient with a Spontaneous Factor VIII Inhibitor
    Marcus E. Carr
    Jan G. Kuhn
    Erika J. Martin
    Ann R. Tidwell
    Maura K. Hagane
    [J]. International Journal of Hematology, 2003, 77 : 308 - 309
  • [26] Effective treatment with recombinant factor VIIa of severe bleeding due to acquired factor VIII inhibitor and acquired thrombocytopathy
    Conesa, V
    Mompel, A
    Lopez, F
    Marin, F
    Ruiz, J
    Navarro, F
    Gomez, A
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (04) : 329 - 330
  • [27] Pseudoprolongation of the prothrombin time during treatment with recombinant factor VIIa for bleeding in a patient with a spontaneous factor VIII inhibitor
    Carr, ME
    Kuhn, JG
    Martin, EJ
    Tidwell, AR
    Hagan, MK
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 77 (03) : 308 - 309
  • [28] COMBINATION IMMUNOSUPPRESSIVE THERAPY AFTER FACTOR-VIII INFUSION FOR ACQUIRED FACTOR-VIII INHIBITOR
    LIAN, ECY
    LARCADA, AF
    CHIU, AYZ
    [J]. ANNALS OF INTERNAL MEDICINE, 1989, 110 (10) : 774 - 778
  • [29] Inhibitor development and efficacy of recombinant vs. plasma-derived factor VIII concentrates in haemophilia A patients
    Siegmund, B.
    Richter, H.
    Pollmann, H.
    Orlovic, M.
    Gottstein, S. .
    Klamroth, R.
    [J]. HAEMOPHILIA, 2008, 14 : 51 - 51
  • [30] Safety of factor VIII inhibitor bypass activity (FEIBA®):: 10-year compilation of thrombotic adverse events
    Ehrlich, HJ
    Henzl, MJ
    Gomperts, ED
    [J]. HAEMOPHILIA, 2002, 8 (02) : 83 - 90
12345